This data suggests a potential neuroprotective role for SGLT-2 inhibitors in addressing cerebrovascular-related cognitive impairments and neuronal damage in the context of Alzheimer’s disease. This evidence concerns the gene SLC5A2 and early-onset autosomal dominant Alzheimer disease.